Skip to content
All resources

BPC-157

What Is BPC-157? The Peptide, Its Origin and the Evidence

SB

By

· 10 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 9 sections
  1. Where did BPC-157 come from?
  2. What is BPC-157, chemically?
  3. How is BPC-157 proposed to work?
  4. What has BPC-157 been studied in, and how far did each line get?
  5. Has BPC-157 been tested in humans?
  6. What is BPC-157's regulatory status?
  7. What is BPC-157 commonly confused with?
  8. How should a researcher read the BPC-157 literature?
  9. Frequently asked questions

BPC-157 is a synthetic peptide of fifteen amino acids, GEPPPGKPADDAGLV, with a molecular weight of about 1,419. It was described in 1993 by Pavel Sikiric's group in Zagreb as a fragment of a larger protein they isolated from gastric juice and named BPC, for "body protection compound". Nearly all of its literature is rodent work, much of it from that one group. No receptor has been identified, no controlled human trial has reported, and it is not an approved medicine anywhere.

The folded lining of the stomach with its mucosal cells, in the style of a micrograph
Illustration in the style of a micrograph, not experimental data: the stomach lining, where the BPC-157 story began.

Where did BPC-157 come from?

The story starts with a hypothesis about the stomach, not with a peptide. In a 1993 overview, Sikiric and colleagues proposed that the stomach, which they described as the largest neuroendocrine organ, initiates a protective counter-response to stress throughout the body, an idea they called organoprotection (PMID 8298609). The same paper reported a newly isolated gastric juice protein of about 40,000 daltons, named BPC, and a 15-amino-acid fragment of it, BPC 157, that the authors thought essential to its activity.

That origin explains two things that still define the compound. First, the early literature is about the gut: ulcers, lesions caused by alcohol and anti-inflammatory drugs, fistulas and intestinal anastomoses. The tendon and ligament work that most people now associate with BPC-157 came later. Second, the claim of unusual breadth was there from the beginning. The 1993 paper described benefit across "practically all organ systems" while noting that the final mechanism was poorly understood. Three decades on, the same two features, breadth of reported effects and an uncharacterised mechanism, are still the central tension in reading this literature.

The material sold today is not extracted from gastric juice. It is the fifteen-residue sequence made by solid-phase synthesis. "Body protection compound" is a name, not a finding.

What is BPC-157, chemically?

PropertyBPC-157
SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
Length15 amino acids (a pentadecapeptide)
Molecular weightAbout 1,419
Other namesPL 14736 (development code); PCO-02 and Bepecin (names on a registered phase 1 study)
ParentA gastric juice protein of about 40 kDa called BPC, as described by its discoverers
Common salt formsAcetate; "arginate" is also marketed
Identified receptorNone

The sequence has four prolines, three of them consecutive, two adjacent aspartates and no cysteine, methionine or tryptophan. Those details matter for analysis and storage more than for biology, and they are covered in BPC-157 stability after reconstitution. What "acetate" and "arginate" mean, and why no published study compares them, is in BPC-157 arginate vs acetate.

How is BPC-157 proposed to work?

The honest summary is that nobody knows its target. Sikiric's 2011 review of the gastrointestinal work lists a wide range of reported actions in rats: strong angiogenic potential, effects on the endothelium and on thrombus formation after aortic anastomosis, interactions with the nitric oxide system (it modifies the effects of both L-arginine and the NO-synthase inhibitor L-NAME), interactions with dopamine and serotonin systems, and behaviour like a free-radical scavenger in liver-injury models (PMID 21548867).

Two threads recur across organs and are the ones most often offered as a mechanism:

  • Angiogenesis. New blood-vessel growth, with VEGF receptor signalling often invoked. This is the link usually drawn to tendon, which is poorly vascularised.
  • The nitric oxide system. The Zagreb group frames BPC-157 as modulating NO signalling in both directions, depending on the model.

A list of pathways that a compound appears to touch is not the same as a mechanism. Without an identified receptor, it is hard to predict what BPC-157 will do in a new tissue, hard to design an antagonist experiment, and hard to rule out that many reported effects are downstream of one unknown action.

There is also a pharmacokinetic puzzle. He and colleagues measured BPC-157 in rats and beagle dogs and reported an elimination half-life of the intact peptide under 30 minutes, with rapid breakdown into small fragments and single amino acids (PMID 36588717). A 2026 biopharmaceutical review by Mateescu and colleagues calls the contrast between that short half-life and effects reported to last hours or days a "pharmacokinetic-pharmacodynamic disconnect" (PMID 42198317). The review is careful about the reason: what is missing is not reported biological activity but basic pharmaceutical science, including characterised formulations, validated pharmacokinetics in people and a development strategy.

What has BPC-157 been studied in, and how far did each line get?

Research areaTypical modelsEvidence stageWhere to read more
Stomach and intestine: ulcers, drug- and alcohol-induced lesions, fistulas, short bowelRat lesion and surgical modelsAnimalKPV vs BPC-157
Tendon, ligament, muscle and boneRat transection and detachment models; tendon cells in cultureAnimal and cellBPC-157 musculoskeletal research
Liver, vascular and nervous-system modelsRat injury and toxicity modelsAnimalSikiric reviews (PMID 21548867)
PharmacokineticsRats and dogsAnimalHe 2022 (PMID 36588717)
PeopleOne retrospective knee-pain case series; one two-person safety pilotUncontrolled human reportsThis page, below

The gut literature is the oldest and largest. The musculoskeletal literature is the one people search for, and its strongest papers are rat models of transected tendon and ligament, with one frequently cited cell-culture study from a group outside Zagreb. A 2025 systematic review from an orthopaedic sports-medicine perspective screened 544 articles and included 36: 35 preclinical studies and a single clinical one (PMID 40756949).

Has BPC-157 been tested in humans?

Barely, and never in a completed controlled trial.

The only published human reports are uncontrolled. In the retrospective knee-pain series reviewed by Vasireddi and colleagues, 7 of 12 patients reported relief lasting more than six months (PMID 40756949). There was no comparison group, so the figure cannot separate any effect of the peptide from natural recovery, expectation or other care. Lee and Burgess published a two-person safety pilot in 2025 (PMID 40131143). Mateescu's review puts the total at fewer than 30 subjects across three uncontrolled pilot studies, none of which used standardised pharmaceutical preparations (PMID 42198317).

The registry record says the same. Under the development code PL 14736, BPC-157 was described as safe in inflammatory bowel disease clinical trials (PMID 21548867), but no results of such trials are available to read. On ClinicalTrials.gov, a phase 1 safety and pharmacokinetics study of PCO-02, "which active ingredient is BPC-157", was registered in Mexico in 2015 with 42 healthy volunteers planned (NCT02637284). Its status is listed as unknown and no results are posted. A small randomised pilot in patients having rotator cuff repair, sponsored by the University of Arkansas, was listed as not yet recruiting in late 2026 (NCT07803250). A registered trial is a plan, not a result.

What is BPC-157's regulatory status?

  • Not approved anywhere. No approval from Health Canada, the FDA or the EMA, for any indication. The 2025 orthopaedic review states plainly that it lacks FDA approval (PMID 40756949).
  • US compounding. The FDA lists BPC-157 in "Category 2", its list of bulk drug substances nominated for pharmacy compounding that may present significant safety risks. The agency cites possible immunogenicity and the difficulty of characterising the peptide and its impurities.
  • Sport. Because it has no approval for human therapeutic use anywhere, it falls under section S0, "non-approved substances", of the World Anti-Doping Agency's Prohibited List. The details are in are peptides banned in sport.
  • Canada. It is not an authorised drug. Material sold here is a research chemical for laboratory use only.

What is BPC-157 commonly confused with?

A naturally occurring hormone. Some reviews describe it as a naturally occurring gastric peptide. What has been published is that its discoverers isolated a larger gastric protein and characterised this fragment of it. The product is a synthetic fifteen-residue peptide.

"Stable" as a shelf-life claim. "Stable gastric pentadecapeptide" refers to the peptide's reported stability in human gastric juice (PMID 21548867). It says nothing about how long a solution lasts in a vial.

TB-500. The two are sold together so often that they read as relatives. They are unrelated molecules from different proteins; see BPC-157 vs TB-500 and what is TB-500.

A blend's evidence. BPC-157 is a component of several multi-peptide vials, examined in inside the KLOW blend and Wolverine Stack vs GLOW. No published study has tested any of those combinations.

GHK-Cu and KPV. Both share BPC-157's marketing vocabulary and little else. The comparisons are in GHK-Cu vs BPC-157, what is GHK-Cu and what is KPV peptide.

How should a researcher read the BPC-157 literature?

Three questions do most of the work. Who ran the study, and is it independent of the Zagreb group? What was the model, and is the endpoint histology, mechanics or behaviour? And was the effect measured against a proper control, with blinding? Independent replication is sparse, and a literature in which one laboratory produced most findings is exactly where that matters. How to read a peptide study sets out the general checklist.

Nothing here is medical, dosing, or therapeutic guidance.

Supplied here for laboratory use: BPC-157. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

Frequently asked questions

What does BPC stand for? Body protection compound. It is the name Sikiric's group gave to a gastric juice protein of about 40 kDa that they isolated in the early 1990s. The "157" identifies the fifteen-amino-acid fragment they characterised. The name reflects the group's organoprotection hypothesis rather than any established effect, and the compound sold today is a synthetic copy of that fragment.

Is BPC-157 a natural peptide? The sequence was described as part of a larger protein found in human gastric juice, but research and commercial material is made by chemical synthesis. No physiological role for the free fifteen-residue fragment in people has been established. "Derived from a natural protein" and "a natural hormone with a known function" are different claims.

What receptor does BPC-157 bind? None has been identified. The literature reports effects on angiogenesis, nitric oxide signalling, and dopamine and serotonin systems, but these are observations in models, not a binding target. That gap is one reason its effects are hard to predict and its development has stalled, as the 2026 Mateescu review discusses.

How many people has BPC-157 been tested in? Fewer than 30 across three uncontrolled pilot reports, according to a 2026 review, and none of them was randomised or used a standardised pharmaceutical preparation. A phase 1 study registered in 2015 has no posted results. In practical terms, there is no controlled human evidence for any use.

Is BPC-157 legal in Canada? It is not an authorised drug in Canada and is not sold for human use. It is supplied as a research chemical for laboratory work. It is also prohibited in sport under the World Anti-Doping Agency's non-approved substances section, which matters to anyone who competes.

Selected Research References

  1. Sikirić P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology, Paris. 1993;87(5):313-327. pubmed.ncbi.nlm.nih.gov/8298609
  2. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632. pubmed.ncbi.nlm.nih.gov/21548867
  3. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. pubmed.ncbi.nlm.nih.gov/36588717
  4. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485-495. pubmed.ncbi.nlm.nih.gov/40756949
  5. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20-24. pubmed.ncbi.nlm.nih.gov/40131143
  6. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. pubmed.ncbi.nlm.nih.gov/42198317

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.